You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Welcome to Astellas' Medicines Availability page, where you can explore the range of our pharmaceutical products available in various locations. We are committed to transparency and providing valuable information related to our products allowing you to understand what Astellas has to offer in each location.
This website contains information about products that may not be available in all locations, or may be available under different trademarks, for different indications, or in different dosages. We only communicate information about our medicines for locations where we are permitted to do so.
Readers should not rely on labels/information from other locations displayed on this website. Always refer to labels/information provided in relation to the relevant location or approved by the relevant national authority.
Entries are based on official, regulated, publicly available information.
Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug.
Any information provided is not intended as medical advice nor should it be used as a substitute for the advice provided by your physician or other healthcare provider. Patients should always consult with their healthcare professional for any further information about their specific treatment.
We encourage you to check back regularly for updates, as our portfolio may expand in response to evolving healthcare needs and regulatory approvals.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
Please find below a list of our products available in Australia.
The information provided may contain links to the relevant publicly available, local regulatory documents (e.g. Summary of Product Characteristics and Patient Information Leaflets, etc.).
Nothing on this site should be considered a solicitation, promotion or advertisement for any drug.
Any information provided is not intended as medical advice nor should it be used as a substitute for the advice provided by your physician or other healthcare provider. Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
We are not permitted to provide specific details relating to our products for Austria on this site.
Readers should not rely on labels/information from other locations displayed on this website.
Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
Please find below a list of our products available in Belgium.
The information provided may contain links to the relevant publicly available, local regulatory documents (e.g. Summary of Product Characteristics and Patient Information Leaflets, etc.).
Nothing on this site should be considered a solicitation, promotion or advertisement for any drug.
Any information provided is not intended as medical advice nor should it be used as a substitute for the advice provided by your physician or other healthcare provider. Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
Please find below a list of our products available in Brazil.
The information provided may contain links to the relevant publicly available, local regulatory documents (e.g. Healthcare Professional Leaflet and Patient Leaflet, etc.).
Nothing on this site should be considered a solicitation, promotion or advertisement for any drug.
Any information provided is not intended as medical advice nor should it be used as a substitute for the advice provided by your physician or other healthcare provider. Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
mirabegrona
cloridrato de tansulosina
succinato de solifenacina
succinato de solifenacina / cloridrato de tansulosina
We are not permitted to provide specific details relating to our products for Bulgaria on this site.
Readers should not rely on labels/information from other locations displayed on this website.
Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
Please find below a list of our products available in Canada.
The information provided may contain links to the relevant publicly available, local regulatory documents (e.g. Summary of Product Characteristics and Patient Information Leaflets, etc.).
Nothing on this site should be considered a solicitation, promotion or advertisement for any drug.
Any information provided is not intended as medical advice nor should it be used as a substitute for the advice provided by your physician or other healthcare provider. Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
For patient information, please refer to Part III of the Product Monograph
For patient information, please refer to Part III of the Product Monograph
For patient information, please refer to Part III of the Product Monograph
Joint Health Canada and Manufacturers Communication: Important Safety Information on Tacrolimus - Risk of Graft Rejection due to Medication Errors: Inadvertent Switching between Different Oral Formulations
For patient information, please refer to Part III of the Product Monograph
For patient information, please refer to Part III of the Product Monograph
For patient information, please refer to the Patient Medication Information section of the Product Monograph
For patient information, please refer to Part III of the Product Monograph
For patient information, please refer to Part III of the Product Monograph
We are not permitted to provide specific details relating to our products for Chile on this site.
Readers should not rely on labels/information from other locations displayed on this website.
Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
Please find below a list of our products available in China.
The information provided may contain links to the relevant publicly available, local regulatory documents (e.g. Summary of Product Characteristics and Patient Information Leaflets, etc.).
Nothing on this site should be considered a solicitation, promotion or advertisement for any drug.
Any information provided is not intended as medical advice nor should it be used as a substitute for the advice provided by your physician or other healthcare provider. Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
(Zolbetuximab for Injection)
(注射用佐妥昔单抗)
查看最新说明书（仅供医学专业人士参考)
( Enfortumab Vedotin for Injection)
(注射用维恩妥尤单抗)
查看最新说明书（仅供医学专业人士参考）
( Enzalutamide Soft Capsules)
(恩扎卢胺软胶囊)
查看最新说明书（仅供医学专业人士参考）
(Gilteritinib Fumarate Tablets)
(富马酸吉瑞替尼片)
查看最新说明书（仅供医学专业人士参考）
(Tacrolimus Capsules)
(他克莫司胶囊)
查看最新说明书（仅供医学专业人士参考）
(Tacrolimus Injection)
(他克莫司注射液)
查看最新说明书（仅供医学专业人士参考）
(Tacrolimus Sustained-release Capsules)
(他克莫司缓释胶囊)
查看最新说明书（仅供医学专业人士参考）
(Tacrolimus Granules)
(他克莫司颗粒)
查看最新说明书（仅供医学专业人士参考）
(Micafungin Sodium for Injection)
(注射用米卡芬净钠)
查看最新说明书（仅供医学专业人士参考）
(Tamsulosin Hydrochloride Sustained Release Capsules)
(盐酸坦索罗辛缓释胶囊)
查看最新说明书（仅供医学专业人士参考）
(Mirabegron Sustained-release Tablets)
(米拉贝隆缓释片)
查看最新说明书（仅供医学专业人士参考）
(Solifenacin Succinate Tablets)
(琥珀酸索利那新片)
查看最新说明书（仅供医学专业人士参考）
(Febuxostat Tablets)
(非布司他片)
查看最新说明书（仅供医学专业人士参考）
We are not permitted to provide specific details relating to our products for Colombia on this site.
Readers should not rely on labels/information from other locations displayed on this website.
Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
We are not permitted to provide specific details relating to our products for Croatia on this site.
Readers should not rely on labels/information from other locations displayed on this website.
Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
Pro informace o léčivých přípravcích společnosti Astellas Pharma s.r.o. a jejich dostupnosti v ČR v českém jazyce, prosím, použijte odkaz ZDE.
Please find below a list of our products available in Czech Republic.
The information provided may contain links to the relevant publicly available, local regulatory documents (e.g. Summary of Product Characteristics and Patient Information Leaflets, etc.).
Nothing on this site should be considered a solicitation, promotion or advertisement for any drug.
Any information provided is not intended as medical advice nor should it be used as a substitute for the advice provided by your physician or other healthcare provider. Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
VPOIS - Publicly accessible professional information service
The obligation to establish this “Publicly accessible professional information service” (VPOIS) arises from Act 378/2007 Coll., as amended.
The marketing authorisation holder is also obliged to make the text of the Package Leaflet (PIL) of human medicinal products accessible to blind and partially sighted persons in an appropriate manner. In case of this need, please write to info@cz.astellas.com
| Product name (active substance) | Package leaflet (PIL) | Summary of Product Characteristics (SmPC) |
On the market in the Czech Republic |
Distributor |
|---|---|---|---|---|
| Advagraf
(tacrolimus) |
Advagraf 0.5mg | Advagraf 0.5mg | Yes | Astellas Pharma s.r.o |
| extended-release capsules | ||||
| Advagraf 1 mg | Yes | Astellas Pharma s.r.o | ||
| extended-release capsules | ||||
| Advagraf 3 mg | Advagraf 3 mg | Yes | Astellas Pharma s.r.o | |
| extended-release capsules | ||||
| Advagraf 5 mg | Advagraf 5 mg | Yes | Astellas Pharma s.r.o | |
| extended-release capsules | ||||
| Betmiga
(mirabegrone) |
Betmiga 25 mg | Betmiga 25 mg | No | Astellas Pharma s.r.o |
| extended-release tablets | ||||
| Betmiga 50 mg | Betmiga 50 mg | Yes | Astellas Pharma s.r.o | |
| extended-release tablets | ||||
| Betmiga 8 mg/ml | Betmiga 8 mg/ml | No | Astellas Pharma s.r.o | |
| granules for prolonged-release oral suspension | ||||
| Evrenzo
(roxadustatum) |
Evrenzo 20 mg | Evrenzo 20 mg | Yes | Astellas Pharma s.r.o |
| film-coated tablets | ||||
| Evrenzo 50 mg | Evrenzo 50 mg | Yes | Astellas Pharma s.r.o | |
| film-coated tablets | ||||
| Evrenzo 70 mg | Evrenzo 70 mg | Yes | Astellas Pharma s.r.o | |
| film-coated tablets | ||||
| Evrenzo 100 mg | Evrenzo 100 mg | Yes | Astellas Pharma s.r.o | |
| film-coated tablets | ||||
| Evrenzo 150 mg | Evrenzo 150 mg | Yes | Astellas Pharma s.r.o | |
| film-coated tablets | ||||
| Modigraf
(tacrolimus) |
Modigraf 0.2 mg | Modigraf 0.2 mg | Yes | Astellas Pharma s.r.o |
| granules for oral suspension | ||||
| Modigraf 1 mg | Modigraf 1 mg | Yes | Astellas Pharma s.r.o | |
| granules for oral suspension | ||||
| Omnic Tocas
(tamsulosin hydrochloride) |
Omnic Tocas 0.4 | Omnic Tocas 0.4 | Yes | Astellas Pharma s.r.o |
| extended-release tablets | ||||
| Padcev
(enfortumab vedotin) |
Padcev 20 mg | Padcev 20 mg | Yes | Astellas Pharma s.r.o |
| powder for concentrate for solution for infusion | ||||
| Padcev 30 mg | Padcev 30 mg | Yes | Astellas Pharma s.r.o | |
| powder for concentrate for solution for infusion | ||||
| Prograf
(tacrolimus) |
Prograf 0.5 mg | Prograf 0.5 mg | Yes | Astellas Pharma s.r.o |
| hard capsules | ||||
| Prograf 1 mg | Prograf 1 mg | Yes | Astellas Pharma s.r.o | |
| hard capsules | ||||
| Prograf 5 mg | Prograf 5 mg | Yes | Astellas Pharma s.r.o | |
| hard capsules | ||||
| Prograf 5 mg/ml | Prograf 5 mg/ml | Yes | Astellas Pharma s.r.o | |
| concentrate for infusion solution | ||||
| Urizia
(solifenacin succinase and tamsulosin hydrochloride ) |
Urizia 6 mg/0.4 mg | Urizia 6 mg/0.4 mg | Yes | Astellas Pharma s.r.o |
| controlled-release tablets | ||||
| Veoza
(fezolinetant) |
Veoza 45 mg | Veoza 45 mg | No | Astellas Pharma s.r.o |
| film-coated tablets | ||||
| Vesicare
(solifenacin succinas) |
Vesicare 5 mg | Vesicare 5 mg | Yes | Astellas Pharma s.r.o |
| film-coated tablets | ||||
| Vesicare 10 mg | Vesicare 10 mg | Yes | Astellas Pharma s.r.o | |
| film-coated tablets | ||||
| Vesicare 1 mg/ml | Vesicare 1 mg/ml | Yes | Astellas Pharma s.r.o | |
| oral suspension | ||||
| Vyloy
(zolbetuximab) |
Vyloy 100 mg | Vyloy 100 mg | No | Astellas Pharma s.r.o |
| powder for concentrate for solution for infusion | ||||
| Xtandi
(enzatulamide) |
Xtandi 40 mg | Xtandi 40 mg | No | Astellas Pharma s.r.o |
| soft capsules | ||||
| Xtandi 40 mg | Xtandi 40 mg | Yes | Astellas Pharma s.r.o | |
| film-coated tablets | ||||
| Xtandi 80 mg | Xtandi 80 mg | No | Astellas Pharma s.r.o | |
| film-coated tablets | ||||
| Xospata
(gilteritinib) |
Xospata 40 mg | Xospata 40 mg | Yes | Astellas Pharma s.r.o |
| film-coated tablets | ||||
We are not permitted to provide specific details relating to our products for Denmark on this site.
Readers should not rely on labels/information from other locations displayed on this website.
Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
We are not permitted to provide specific details relating to our products for Finland on this site.
Readers should not rely on labels/information from other locations displayed on this website.
Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
The information provided may contain links to the relevant publicly available, local regulatory documents (e.g. Summary of Product Characteristics and Patient Information Leaflets, etc.).
Nothing on this site should be considered a solicitation, promotion or advertisement for any drug.
Any information provided is not intended as medical advice nor should it be used as a substitute for the advice provided by your physician or other healthcare provider. Patients should always consult with their healthcare professional for any further information about their specific treatment
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
In accordance with Article L. 5121-1-3 of the Public Health Code, below is the list of active ingredients of medicines for which Astellas Pharma France is responsible for marketing and/or holds marketing authorizations:
Nom
DCI
ADVAGRAF™ 0.5 mg, gélules à libération prolongée
tacrolimus
ADVAGRAF™ 1 mg, gélules à libération prolongée
tacrolimus
ADVAGRAF™ 3 mg, gélules à libération prolongée
tacrolimus
ADVAGRAF™ 5 mg, gélules à libération prolongée
tacrolimus
BETMIGA™ 25 mg, comprimés à libération prolongée
mirabegron
BETMIGA™ 50 mg, comprimés à libération prolongée
mirabegron
EVRENZO™ 20 mg, comprimé pelliculé
roxadustat
EVRENZO™ 50 mg, comprimé pelliculé
roxadustat
EVRENZO™ 70 mg, comprimé pelliculé
roxadustat
EVRENZO™ 100 mg, comprimé pelliculé
roxadustat
EVRENZO™ 150 mg, comprimé pelliculé
roxadustat
JOSACINE™ 125 mg/5 ml, granulés pour suspension buvable
josamycine
JOSACINE™ 250 mg/5 ml, granulés pour suspension buvable
josamycine
JOSACINE™ 500 mg/5 ml, granulés pour suspension buvable
josamycine
JOSACINE™ 500 mg, comprimé pelliculé
josamycine
JOSACINE™ 1000 mg, comprimé dispersible
josamycine
MODIGRAF™ 0.2 mg, granulés pour suspension buvable
tacrolimus
MODIGRAF™ 1 mg, granulés pour suspension buvable
tacrolimus
OMEXEL™ L.P. 0.4 mg, comprimé pelliculé à libération prolongée
tamsulosine
OMIX™ LP 0.4 mg, microgranules à libération prolongée en gélule
tamsulosine
PADCEV™ 20 mg poudre pour solution à diluer pour perfusion
enfortumab Vedotin
PADCEV™ 30 mg poudre pour solution à diluer pour perfusion
enfortumab Vedotin
PROGRAF™ 0.5 mg, gélule
tacrolimus
PROGRAF™ 1 mg, gélule
tacrolimus
PROGRAF™ 5 mg, gélule
tacrolimus
PROGRAF™ 5 mg/ml, solution à diluer pour perfusion
tacrolimus
VEOZA™ 45 mg, comprimé pelliculé
fézolinétant
VESICARE™ 5 mg, comprimé pelliculé
solifénacine
VESICARE™ 10 mg, comprimé pelliculé
solifénacine
VESICARE™ 1 mg/ml, suspension buvable
solifénacine
VYLOY™ 100 mg poudre pour solution à diluer pour perfusion
zolbétuximab
XOSPATA™ 40 mg, comprimé pelliculé
gilteritinib
XTANDI™ 40 mg, comprimé pelliculé
enzalutamide
Please find below a list of our products available in France.
Read the Summary of Product Characteristics, the Patient Information Leaflet, as well as the opinion of the Transparency Commission:
Read the Summary of Product Characteristics, the Patient Information Leaflet, as well as the opinion of the Transparency Commission:
For our medicines that have been subject to additional risk minimisation measures, you will find the documents by clicking here.
Read the Summary of Product Characteristics, the Patient Information Leaflet, as well as the opinion of the Transparency Commission:
For our medicines that have been subject to additional risk minimisation measures, you will find the documents by clicking here.
Read the Summary of Product Characteristics, the Patient Information Leaflet, as well as the opinion of the Transparency Commission:
Read the Summary of Product Characteristics, the Patient Information Leaflet, as well as the opinion of the Transparency Commission:
Read the Summary of Product Characteristics, the Patient Information Leaflet, as well as the opinion of the Transparency Commission:
Read the Summary of Product Characteristics, the Patient Information Leaflet, as well as the opinion of the Transparency Commission:
Read the Summary of Product Characteristics, the Patient Information Leaflet, as well as the opinion of the Transparency Commission:
Read the Summary of Product Characteristics, the Patient Information Leaflet, as well as the opinion of the Transparency Commission:
Read the Summary of Product Characteristics, the Patient Information Leaflet, as well as the opinion of the Transparency Commission:
Read the Summary of Product Characteristics, the Patient Information Leaflet, as well as the opinion of the Transparency Commission:
Read the Summary of Product Characteristics, the Patient Information Leaflet, as well as the opinion of the Transparency Commission:
Read the Summary of Product Characteristics and the Patient Information Leaflet:
For our medicines that have been subject to additional risk minimisation measures, you will find the documents by clicking here.
Please find below a list of our products available in Germany.
The information provided may contain links to the relevant publicly available, local regulatory documents (e.g. Summary of Product Characteristics and Patient Information Leaflets, etc.).
Nothing on this site should be considered a solicitation, promotion or advertisement for any drug.
Any information provided is not intended as medical advice nor should it be used as a substitute for the advice provided by your physician or other healthcare provider. Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
Upon request, you can have the package leaflet read aloud to you by our medical information service.
You can reach them Monday through Friday from 8 a.m. to 6 p.m. at 0800 111 4544.
(Advagraf™ 0.5 mg/1 mg/3 mg/5 mg delayed-release hard capsules)
(Betmiga™ 25 mg/50 mg delayed-release tablets)
(Evrenzo™ 20 mg/50 mg/70 mg/100 mg/150 mg film-coated tablets)
(Modigraf™ granules for oral suspension)
(Omnic Ocas™ 0,4 mg extended-release tablets)
(Padcev™ powder for concentrate for solution for infusion)
(Prograf™ 0,5 mg/1 mg/5 mg hard capsules)
(Prograf™ 5 mg/ml powder for solution for infusion)
(Tamsu-astellas™ 0,4 mg modified-release hard capsule)
(Veoza™ 45 mg film-coated tablets)
(Vesikur™ 1 mg/ml oral suspension)
(Vesikur™ 5 mg/10 mg film-coated tablets)
(Vyloy™ 100 mg/300 mg powder for concentrate for solution for infusion)
(Xospata™ 40 mg film-coated tablets)
(Xtandi™ 40 mg/80 mg F film-coated tablets)
(Advagraf™ 0.5 mg/1 mg/3 mg/5 mg delayed-release hard capsules)
(Betmiga™ 25 mg/50 mg delayed-release tablets)
(Evrenzo™ 20 mg/50 mg/70 mg/100 mg/150 mg film-coated tablets)
(Modigraf™ granules for oral suspension)
(Omnic Ocas™ 0.4 mg extended-release tablets)
(Padcev™ powder for concentrate for solution for infusion)
(Prograf™ 0,5 mg/1 mg/5 mg hard capsules)
(Prograf™ 5 mg/ml powder for solution for infusion)
(Tamsu-astellas™ 0,4 mg modified-release hard capsule)
(Veoza™ 45 mg film-coated tablets)
(Vesikur™ 1 mg/ml oral suspension)
(Vesikur™ 5 mg/10 mg film-coated tablets)
(Vyloy™ 100 mg/300 mg powder for concentrate for solution for infusion)
(Xospata™ 40 mg film-coated tablets)
(Xtandi™ 40 mg/80 mg F film-coated tablets)
(Advagraf™ 0.5 mg/1 mg/3 mg/5 mg delayed-release hard capsules)
(Betmiga™ 25 mg/50 mg delayed-release tablets)
(Evrenzo™ 20 mg/50 mg/70 mg/100 mg/150 mg film-coated tablets)
(Modigraf™ granules for oral suspension)
(Omnic Ocas™ 0.4 mg extended-release tablets)
(Padcev™ powder for concentrate for solution for infusion)
(Prograf™ 0,5 mg/1 mg/5 mg hard capsules)
(Prograf™ 5 mg/ml powder for solution for infusion)
(Tamsu-astellas™ 0,4 mg modified-release hard capsule)
(Veoza™ 45 mg film-coated tablets)
(Vesikur™ 1 mg/ml oral suspension)
(Vesikur™ 5 mg/10 mg film-coated tablets)
(Vyloy™ 100 mg/300 mg powder for concentrate for solution for infusion)
(Xospata™ 40 mg film-coated tablets)
(Xtandi™ 40 mg/80 mg F film-coated tablets)
PADCEV-Information - Anschreiben für Ärzte und Apotheker
PADCEV (Enfortumab Vedotin) - Cover letter for doctors and pharmacists
PADCEV-Information - Gebrauchsinformation
PADCEV (Enfortumab Vedotin) - Patient Information Leaflet
PADCEV-Schulungsmaterial - Patientenkarte
PADCEV (Enfortumab Vedotin) Educational Material - Patient Card
You are welcome to order printed copies of the PADCEV training materials from us. Simply contact us. Use "PADCEV Information Package" as the subject and indicate how many copies you need in the email.
XOSPATA Informationsbroschüre (PDF)
XOSPATA (gilteritinib) - Differentiation Syndrome Information Brochure for Physicians
XOSPATA (gilteritinib) - patient card
We are not permitted to provide specific details relating to our products for Greece on this site.
Readers should not rely on labels/information from other locations displayed on this website.
Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
We are not permitted to provide specific details relating to our products for Hong Kong on this site.
Readers should not rely on labels/information from other locationsdisplayed on this website.
Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
We are not permitted to provide specific details relating to our products for Hungary on this site.
Readers should not rely on labels/information from other locations displayed on this website.
Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
We are not permitted to provide specific details relating to our products for India on this site.
Readers should not rely on labels/information from other locations displayed on this website.
Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
We are not permitted to provide specific details relating to our products for Indonesia on this site.
Readers should not rely on labels/information from other locations displayed on this website.
Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
Please find below a list of our products available in Ireland.
The information provided may contain links to the relevant publicly available, local regulatory documents (e.g. Summary of Product Characteristics and Patient Information Leaflets, etc.).
Nothing on this site should be considered a solicitation, promotion or advertisement for any drug.
Any information provided is not intended as medical advice nor should it be used as a substitute for the advice provided by your physician or other healthcare provider. Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
Further information on the above products can be found at www.medicines.ie
Please find below a list of our products available in Israel.
The information provided may contain links to the relevant publicly available, local regulatory documents (e.g. Summary of Product Characteristics and Patient Information Leaflets, etc.).
Nothing on this site should be considered a solicitation, promotion or advertisement for any drug.
Any information provided is not intended as medical advice nor should it be used as a substitute for the advice provided by your physician or other healthcare provider. Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
For more information:
For more information:
Do not replace with another tacrolimus preparation, unless the doctor from the transplant clinic you are treated in approves that.
For more information:
For more information:
Padcev 20mg
Padcev 30mg
Product Supply Queries
If you have a query relating to the supply of any Astellas Pharma Ltd. product, please contact Novolog, Service Center landline: +972-8-6604444 Email: cscenter@novolog.co.il
We are not permitted to provide specific details relating to our products for Italy on this site.
Readers should not rely on labels/information from other locations displayed on this website.
Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
For information about products available in Japan, please visit here.
For information about products available in Korea, please visit here.
We are not permitted to provide specific details relating to our products for Malaysia on this site.
Readers should not rely on labels/information from other locations displayed on this website.
Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
We are not permitted to provide specific details relating to our products for Mexico on this site.
Readers should not rely on labels/information from other locations displayed on this website.
Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
Please find below a list of our products available in the Netherlands.
The information provided may contain links to the relevant publicly available, local regulatory documents (e.g. Summary of Product Characteristics and Patient Information Leaflets, etc.).
Nothing on this site should be considered a solicitation, promotion or advertisement for any drug.
Any information provided is not intended as medical advice nor should it be used as a substitute for the advice provided by your physician or other healthcare provider. Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
Additional risk minimisation material
Additional risk minimisation material
We are not permitted to provide specific details relating to our products for Norway on this site.
Readers should not rely on labels/information from other locations displayed on this website.
Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
Please find below a list of our products available in the Philippines.
The information provided may contain links to the relevant publicly available, local regulatory documents (e.g. Summary of Product Characteristics and Patient Information Leaflets, etc.).
Nothing on this site should be considered a solicitation, promotion or advertisement for any drug.
Any information provided is not intended as medical advice nor should it be used as a substitute for the advice provided by your physician or other healthcare provider. Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
Prostate cancer:
Immunosuppressant:
Benign Prostatic Hyperplasia:
Overactive Bladder:
Anti-gout:
Readers should not rely on labels/information from other locations displayed on this website.
Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
We are not permitted to provide specific details relating to our products for Portugal on this site.
Readers should not rely on labels/information from other locations displayed on this website.
Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
We are not permitted to provide specific details relating to our products for Romania on this site.
Readers should not rely on labels/information from other locations displayed on this website.
Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
We are not permitted to provide specific details relating to our products for Singapore on this site.
Readers should not rely on labels/information from other locations displayed on this website.
Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
We are not permitted to provide specific details relating to our products for Slovakia on this site.
Readers should not rely on labels/information from other locations displayed on this website.
Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
We are not permitted to provide specific details relating to our products for Slovenia on this site.
Readers should not rely on labels/information from other locations displayed on this website.
Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
We are not permitted to provide specific details relating to our products for Spain on this site.
Readers should not rely on labels/information from other locations displayed on this website. Always refer to labels/infomation approved by the Spanish national health authority available at https://cima.aemps.es/cima/publico/home.html
Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
We are not permitted to provide specific details relating to our products for Sweden on this site.
Readers should not rely on labels/information from other locations displayed on this website.
Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
We are not permitted to provide specific details relating to our products for Switzerland on this site.
Readers should not rely on labels/information from other locations displayed on this website.
Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
Please find below a link to a list of our products available in Taiwan.
The information provided may contain links to the relevant publicly available, local regulatory documents (e.g. Summary of Product Characteristics and Patient Information Leaflets, etc.).
Nothing on this site should be considered a solicitation, promotion or advertisement for any drug.
Any information provided is not intended as medical advice nor should it be used as a substitute for the advice provided by your physician or other healthcare provider. Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
Search for products available in Taiwan here: https://mcp.fda.gov.tw/im
We are not permitted to provide specific details relating to our products for Thailand on this site.
Readers should not rely on labels/information from other locations displayed on this website.
Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
T-MEA locations consist of Turkey, United Arab Emirates (UAE), Kingdom of Saudi Arabia, Egypt and South Africa
RHQ KSA located in Ryiadh, KSA is acting as a regional headquater for certain countries. For the details, please ask RHQ KSA representative.
We are not permitted to provide specific details relating to our products for T-MEA on this site.
Readers should not rely on labels/information from other locations displayed on this website.
Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
Please find below a list of our products available in the United Kingdom.
The information provided may contain links to the relevant publicly available, local regulatory documents (e.g. Summary of Product Characteristics and Patient Information Leaflets, etc.).
Nothing on this site should be considered a solicitation, promotion or advertisement for any drug.
Any information provided is not intended as medical advice nor should it be used as a substitute for the advice provided by your physician or other healthcare provider. Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
enzalutamide
gilteritinib fumarate
enfortubmab vedotin
tacrolimus monohydrate
tacrolimus monohydrate
tacrolimus monohydrate
tamsulosin hydrochloride
mirabegron
tamsulosin hydrochloride, solifenacin succinate
solifenacin succinate
Please find below a list of our products available in the United States.
The information provided may contain links to the relevant publicly available, local regulatory documents (e.g. Summary of Product Characteristics and Patient Information Leaflets, etc.).
Nothing on this site should be considered a solicitation, promotion or advertisement for any drug.
Any information provided is not intended as medical advice nor should it be used as a substitute for the advice provided by your physician or other healthcare provider. Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
(tacrolimus) extended-release capsules
(tacrolimus) capsules, granules and injection
(isavuconazonium sulfate) for injection and capsules
(enzalutamide) capsules
(enzalutamide) tablets
(gilteritinib) tablets
(enfortumab vedotin-ejfv) for injection, for intravenous use
(zolbetuximab-clzb) for injection, for intravenous use
(mirabegron) extended-release tablets
(mirabegron for extended-release) oral suspension
(solifenacin succinate) oral suspension
(fezolinetant) tablets
All trademarks are Astellas' except AmBisome is a registered trademark of Gilead Sciences, Inc.
Additional Resources relevant to our products available in the United States:
We are not permitted to provide specific details relating to our products for Vietnam on this site.
Readers should not rely on labels/information from other locations displayed on this website.
Patients should always consult with their healthcare professional for any further information about their specific treatment.
Healthcare professionals seeking information on our medicines or other education resources, please visit here.
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?